Direct compression of 408 mg lymecycline tablet cores requires strict moisture and lubricant control because lymecycline, as a tetracycline-derived API, is sensitive to acid-catalysed epimerization and oxidative discolouration. The 408 mg dose corresponds to 300 mg tetracycline base. A representative core formula for a 408 mg potency tablet includes lymecycline 408 mg, lactose monohydrate 240 mg, microcrystalline cellulose 50 mg, crospovidone 14 mg, colloidal silicon dioxide 3 mg, and magnesium stearate 7 mg, giving a total core mass of 722 mg. Lactose monohydrate is selected as a crystalline diluent because it contributes low equilibrium moisture under 25°C/60% RH long-term storage conditions described in ICH Q1A, while microcrystalline cellulose serves as dry binder and crospovidone provides wicking disintegration. Blending is performed in a bin blender at 12 rpm for 15 min after geometric pre-mix of colloidal silicon dioxide and API through a 600 µm screen. Magnesium stearate is added last and blended for 3 min at 12 rpm. Extended lubrication beyond 5 min at this speed is avoided because hydrophobic film formation on lymecycline particles can reduce dissolution rate under Ph. Eur. 2.9.3 conditions. Compression runs on a 16-station rotary tablet press with 19 mm × 9 mm oval punches, average compression force 12–18 kN, turret speed 25–35 rpm, and tablet hardness 70–110 N. Friability remains below 1.0% w/w when tested per Ph. Eur. 2.9.7, and disintegration of uncoated cores is within 15 min in water at 37°C ±2°C per Ph. Eur. 2.9.1. Dissolution testing follows Ph. Eur. 2.9.3 apparatus II, 50 rpm, 900 mL dilute hydrochloric acid pH 1.2 at 37°C. Published product-specific acceptance windows for lymecycline tablets are limited, so multi-level acceptance under the general monograph Ph. Eur. 0478 for tablets applies. Bulk API moisture must not exceed 2.0% w/w by Ph. Eur. 2.5.12 Karl Fischer titration before dispensing, and blending rooms are maintained at 21°C ±2°C and ≤40% RH. Elemental impurity risk assessment follows ICH Q3D for oral daily intake. If palladium or nickel is used in upstream synthesis, raw material screening limits are set from permitted daily exposure values. Release is limited to uncoated cores intended for subsequent film coating or immediate packaging. Uncoated cores are not final dosage forms.

What Limits Encapsulation Speed in High-Dose Lymecycline Capsule Cores?

Hard gelatin capsule filling of lymecycline is constrained by the API’s hygroscopicity and the fill’s tap density window. A representative direct-fill powder blend for size 0 capsules contains lymecycline 408 mg, pregelatinized starch 80 mg, lactose monohydrate 85 mg, talc 12 mg, and magnesium stearate 3 mg, yielding a fill weight of 588 mg per capsule. Tap density is controlled between 0.55 g/mL and 0.70 g/mL using Ph. Eur. 2.9.34 bulk and tapped density testing. Values below 0.55 g/mL cause inconsistent dosator fill weight on a 30,000 capsules/h automatic capsule filler, while values above 0.70 g/mL generate excessive fill plug hardness and shell deformation. The filler uses a dosator station with compaction pin set to 5 mm insertion depth and ejection stroke calibrated to 0.5 mm above the capsule body rim. Capsule shell moisture is held at 13–16% w/w, and fill LOD is held at or below 2.5% w/w by Ph. Eur. 2.5.12 to prevent shell brittleness at the body shoulder. Dissolution testing is performed with sinkers in 900 mL dilute HCl pH 1.2, apparatus II at 50 rpm, per Ph. Eur. 2.9.3. Moisture transfer into the shell is assessed after 24 h at 25°C/60% RH by comparing shell splitting rate and dissolution failures. The capsule quality is monitored every 15 min on the filling line. Individual fill mass deviation beyond ±5% of 588 mg or average mass of 10 capsules outside 588 mg ±3% triggers line stop and filling station recalibration. The dosage-form monograph is Ph. Eur. 0016 for capsules, with uniformity of dosage units assessed by Ph. Eur. 2.9.40. Finished capsules are packed in aluminium-aluminium blisters only after 48 h stabilization at 25°C ±2°C and ≤40% RH. The moisture-protective packaging prevents subsequent moisture uptake that would raise LOD and reduce physical stability of the shell.

Granule Growth, Ethanol Binder Addition, and Sachet Fill Uniformity

For lymecycline granules intended for oral suspension, aqueous granulation is replaced by an absolute-ethanol binder system because tetracycline degradation accelerates in acidic aqueous media. A 5% w/w povidone K30 solution in absolute ethanol is added to a high-shear granulator containing lymecycline 408 mg per unit dose, mannitol 300 mg, microcrystalline cellulose 35 mg, and sodium starch glycolate 15 mg. Mannitol is used as a water-soluble, non-hygroscopic crystalline filler to improve reconstitution and reduce residual moisture sensitivity of the granule. Granulation proceeds with impeller tip speed 2.5–4.0 m/s and chopper speed 1500–2500 rpm until wet mass particles pass a 1.25 mm screen. Drying is carried out in a fluid-bed dryer with inlet air temperature 40°C ±2°C and inlet air dew point ≤ -20°C. Drying stops when residual ethanol by headspace gas chromatography per Ph. Eur. 2.2.28 falls below 500 ppm and granule LOD is 1.0–2.0% w/w by Ph. Eur. 2.5.12. Sieve analysis according to Ph. Eur. 2.9.38 shows the final granule fraction between 0.250 mm and 0.850 mm must exceed 80% w/w. Oversized granules retard reconstitution in 100 mL potable water, while undersized granules segregate during sachet filling. Fill weight per sachet is 1.85 g, dispensed on a vertical form-fill-seal line with auger fill tolerance ±4% and sealed under nitrogen-flushed atmosphere. After reconstitution, the suspension is a white to off-white homogeneous liquid with pH 6.0–7.5. It is stored at 2–8°C and used within 7 days. Microbiological quality of the reconstituted suspension is evaluated by Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13. The granule monograph Ph. Eur. 0499 applies to the intermediate. Single-dose sachets are released only after fill weight and moisture limits are met. Published data for this specific lymecycline granule formulation is limited, so general monograph acceptance criteria control release.

When Aseptic Filtration Replaces Terminal Sterilization for Freeze-Dried Injection

Injectable lymecycline is processed as a lyophilized powder because aqueous solution stability does not permit terminal moist-heat sterilization without unacceptable degradation. Bulk solution is prepared in Water for Injections at 8–12°C, with mannitol 50 mg per vial as cryoprotectant and bulking agent. The solution pH is adjusted to 6.0–7.0 with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide. Acetate, citrate, or phosphate buffers are avoided because tetracycline derivatives can complex with multivalent ions and reduce chemical stability. The solution is passed through a 0.22 µm PVDF membrane filter at differential pressure ≤1.0 bar, followed by filling into 10 mL Type I glass vials at 5.0 mL ±0.15 mL. Lyophilization proceeds with freezing at -40°C for 4 h, primary drying at -20°C and 0.20 mbar for 24 h, and secondary drying at 25°C and 0.05 mbar until cake moisture is below 1.0% w/w by Karl Fischer titration. The finished cake is off-white to pale yellow. Reconstitution time in 5 mL WFI must be less than 60 s with gentle swirling, and the reconstituted solution is inspected for visible particles per Ph. Eur. 2.9.20. Sub-visible particulate matter is controlled to ≤6000 particles per vial at ≥10 µm and ≤600 particles per vial at ≥25 µm per Ph. Eur. 2.9.19. Sterility testing follows Ph. Eur. 2.6.1. Bacterial endotoxin limits are calculated from the maximum daily parenteral dose under Ph. Eur. 2.6.14, with published product-specific endotoxin limits for lymecycline injection limited. The powder for injection complies with the general monograph Ph. Eur. 0520 for powders for injections. Each single-dose vial contains a lyophilized cake equivalent to one parenteral dose and is sealed with bromobutyl rubber stopper and aluminium flip-off cap after nitrogen overlay. Residual oxygen in headspace is held below 2.0% v/v by gas analysis.

Film-coating of lymecycline tablet cores uses a non-enteric, low-moisture aqueous dispersion only when process exhaust control is sufficient to keep core moisture below 2.5% w/w. A perforated pan coater with 36-inch pan, 6–10 rpm pan speed, 45–50°C inlet air temperature, 20–25°C product bed temperature, and 8–12 g/min spray rate applies an Opadry II aqueous film coat to a 3.0% w/w weight gain. The coating dispersion is 12% w/w solids in purified water and is sprayed through a 0.8 mm nozzle at atomizing air pressure 1.8–2.2 bar. Exhaust air dew point is held ≤5°C. Under these conditions, core LOD remains below 2.5% w/w by Ph. Eur. 2.5.12 at the end of coating. If ambient humidity exceeds 60% RH, pre-warming of cores at 40°C for 30 min and post-coating drying at 40°C for 15 min are added. Coated tablets are tested for disintegration, which must occur within 30 min in water at 37°C ±2°C per Ph. Eur. 2.9.1. Coating adhesion is checked by friability testing per Ph. Eur. 2.9.7 with no film peeling or cracking after 100 rotations. Coated tablet mass uniformity follows Ph. Eur. 2.9.5, with individual mass deviation not more than ±5% of the average mass and not more than two tablets outside ±3%. The coated tablets are packed into aluminium-aluminium blisters only after residual moisture check. The moisture-protective blister is sealed at 0.35–0.45 MPa jaw pressure and 135–145°C sealing temperature to maintain low moisture ingress over shelf life. Published stability data under this specific aqueous coating protocol is limited. The process is therefore validated at pilot scale before full commercial batches. This film-coated tablet is the final oral solid dosage form for 408 mg lymecycline.